Drugs / GMI-1359
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04197999 | Nov 2019 → Aug 2021 | hormone receptor-positive breast cancer | GlycoMimetics Incorporated | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02931214 | Aug 2016 → Oct 2017 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GMI-1359 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02931214 ↗ |
| Route | Intravenous | “single ascending IV doses” NCT02931214 ↗ |